Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

The role of FDG PET/CT in staging and restaging primary bone lymphoma

Yiyan Liu
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 567;
Yiyan Liu
1Radiology Rutgers University, New Jersey Medical School-University Hospital Newark NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

567

Objectives: Primary bone lymphoma (PBL) is one of the rarest primary bone malignancies. Very limited data are available about the role of FDG PET/CT in PBL.

Methods: 16 relevant patients had FDG PET/CT for staging or staging/restaging PBL. The cases with extraskeletal lesions such as lymphadenopathy or with osseous involvements in disseminated lymphoma were excluded based on the definition of PBL. FDG PET/CT findings were correlated to pathologic and/or anatomic image information.

Results: FDG PET/CT was positive with markedly increased uptake in all known PBL lesions, with a sensitivity of 100%. In 15/16 (93.8%) cases, the bone lesions infiltrated the adjacent soft tissue with visible soft tissue components. Except for known primary bone lesion, FDG PET/CT showed additional 24 bone lesions in 7 patient, which accounted for 44% of all cases. With SUVmax 2.5 as a cutoff for differentiating residual lymphoma from metabolically inactive disease on restaging scan, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of FDG PET/CT for PBL were 100% (4/4), 75% (9/12), 57% (4/7) and 100% (9/9), respectively. The diagnostic accuracy of restaging FDG PET/CT was 81% (13/16). 2 of 3 false positive scans were due to post-therapeutic osteonecrosis.

Conclusion: FDG PET/CT is sensitive for demonstrating PBL which is typically highly FDG avid, and has the ability to depict extraskeletal soft tissue involvement and additional bone lesions on staging. More importantly, FDG PET/CT may accurately and reliably evaluate therapeutic response with excellent sensitivity and NPV. However, false positive FDG uptake poses a concern on restaging PET/CT. Posttherapeutic osteonecrosis is a potential source of false positive findings on FDG PET/CT.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The role of FDG PET/CT in staging and restaging primary bone lymphoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The role of FDG PET/CT in staging and restaging primary bone lymphoma
Yiyan Liu
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 567;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The role of FDG PET/CT in staging and restaging primary bone lymphoma
Yiyan Liu
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 567;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Proton Range Verification with PET Imaging in Brain and Head and Neck Cancers
Show more Oncology, Clinical Diagnosis Track

Lymphoma - Adult

  • Use 18F-FDG PET in initial assessment of primary central nervous system lymphoma
  • Staging Hodgkin Lymphoma Using PET - Can We Safely Exclude Bone Marrow Involvement?
  • Evolving Role of Global Disease Burden Assessment by Novel Quantitative Technique in Patients with Lymphoma Following Therapeutic Intervention
Show more Lymphoma - Adult

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire